Charles River Laboratories International’s (CRL) “Neutral” Rating Reiterated at UBS Group

UBS Group reiterated their neutral rating on shares of Charles River Laboratories International (NYSE:CRL) in a research note released on Friday, Marketbeat reports. They currently have a $185.00 price target on the medical research company’s stock, down from their prior price target of $250.00.

Several other brokerages have also weighed in on CRL. Robert W. Baird decreased their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. William Blair reissued an “outperform” rating on shares of Charles River Laboratories International in a research report on Tuesday, January 14th. Finally, Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $209.00.

Charles River Laboratories International Trading Down 1.2 %

CRL stock opened at $163.77 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. The business has a fifty day simple moving average of $190.64 and a 200-day simple moving average of $198.40. Charles River Laboratories International has a 52 week low of $160.85 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the business earned $2.72 earnings per share. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities research analysts expect that Charles River Laboratories International will post 10.18 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

A number of institutional investors have recently modified their holdings of CRL. Acadian Asset Management LLC bought a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $110,000. American Century Companies Inc. raised its holdings in shares of Charles River Laboratories International by 4.6% in the second quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock valued at $1,354,000 after purchasing an additional 291 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Charles River Laboratories International by 12.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,906 shares of the medical research company’s stock worth $1,640,000 after purchasing an additional 850 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Charles River Laboratories International by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 561,075 shares of the medical research company’s stock valued at $115,912,000 after purchasing an additional 93,682 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its stake in Charles River Laboratories International by 74.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock valued at $833,000 after buying an additional 1,721 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).